Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained from subject's parents or legally acceptable representative before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.)~* Pre-pubertal status (males aged from 4 to 11 \[both inclusive\], females aged from 4 to 9 \[both inclusive\]): an absence of breast development in females (Tanner 1 only) and testicular volume below 4 mL in males~* Growth hormone level above 10 ng/mL following a stimulation test (test result within 6 months from screening can be used)~* Height below 3 percentile~* Bone age below or equal to 12 year~* Epiphyses confirmed as open in patients at least 10 years or more of age~Exclusion Criteria:~* Known presence of one or more pituitary hormone deficiencies (ACTH (adrenocorticotropic hormone), ADH (antidiuretic hormone), FSH (follicle-stimulating hormone), LH (luteinising hormone), TSH (thyroid-stimulating hormone))~* Known primary hypothyroidism, adrenal insufficiency or hypogonadism (treated or untreated)~* Specific types of growth failure including, but not limited to, known chromosomal abnormalities associated with growth failure and altered sensitivity to growth hormone~* Bone age is advanced over chronological age more than 3 years~* Active malignancy, CNS (central nervous system) trauma, active chemotherapy or radiation therapy for neoplasia~* Prior history of intracranial hypertension~* Hypertrophic cardiomyopathy

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- hGH:12months treatment (Type: EXPERIMENTAL): None
- hGH: 6 month un-treatment + 6 month treatment (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).